
Loading, please wait...

Loading, please wait...

The Delhi High Court recently heard a case of a three-year-old child diagnosed with LRBA deficiency. Consequently, this case highlights the strict criteria for rare disease financial assistance under the NPRD 2021. Specifically, the Union Government opposes the child's plea because her condition does not appear on the notified list. Therefore, she currently lacks access to lifesaving financial support.
LRBA deficiency represents a rare genetic immune disorder that severely impairs immune system regulation. As a result, patients experience recurrent life-threatening infections and severe multi-system autoimmune complications. Specialists at AIIMS Delhi and CMC Vellore confirmed this diagnosis using whole-genome sequencing. Ultimately, clinical experts concluded that an allogeneic hematopoietic stem cell transplant is the only curative option. However, this complex procedure costs approximately Rs 40 lakh, placing an immense burden on the family.
For instance, the NPRD 2021 framework provides substantial financial support up to Rs 50 lakh per patient. However, the policy limits this assistance to only 63 notified rare diseases. Furthermore, since the policy omits LRBA deficiency from this list, the government rejected the petitioner's funding request. Additionally, the Centre maintained that expanding the disease list is strictly a policy decision. Thus, judicial intervention cannot mandate changes to the current executive policy framework. In addition, the government noted that public health remains primarily under State Government jurisdiction.
Q1: What is LRBA deficiency?
LRBA deficiency is a rare and severe genetic immune disorder caused by mutations in the LRBA gene. It severely impairs immune regulation, leading to frequent infections, anemia, and autoimmune complications across multiple organs.
Q2: Why did the government deny funding under the NPRD 2021?
The Union Government denied assistance because LRBA deficiency is not currently among the 63 notified rare diseases covered under the National Policy for Rare Diseases (NPRD), 2021 framework.
Q3: What is the maximum financial aid available under NPRD 2021?
The National Policy for Rare Diseases provides financial support of up to Rs 50 lakh per eligible patient, with diagnostic and treatment requests routed through 15 designated Centres of Excellence.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


A three-year-old child's petition for LRBA deficiency treatment highlights the strict limits of India's NPRD 2021. Since the genetic condition is not listed among the 63 notified diseases, the Centre has declined funding, arguing that policy expansion is an executive rather than a judicial decision.
last month

A parliamentary panel has urged the FSSAI to finalise front-of-pack nutrition labelling regulations without further delay. The committee stressed that simple, color-coded indicators for sugar and clear warning labels are vital to combat dietary non-communicable diseases and guide informed consumer choices.
3 days back

A comprehensive analysis of the NFHS-5 data regarding postpartum anemia in India, exploring the prevalence, severity, and the socioeconomic and regional factors contributing to this public health challenge for clinicians seeking to improve maternal health outcomes.
Last week

A study in Greece reveals that 46-80% of heatwave deaths are linked to climate change. This analysis explores the implications for public health and clinical practice, particularly for elderly and vulnerable populations facing rising global temperatures in regions like India.
2 weeks back

Nearly 80% of Indians suffer from inadequate Vitamin D, causing silent bone weakening and sudden fractures. This expert guide reviews why mega-dose therapy is critical for high-risk patients, the key factors driving widespread deficiency, and the mandatory medical evaluations needed to protect skeletal health.
last month

A parliamentary standing committee has directed FSSAI to expedite front-of-pack nutrition labelling regulations. The panel highlighted that over two years of delay since the 2022 draft notification leaves consumers relying on complex numerical labels, urging simple color-coded sugar indicators and warnings.
3 days back